Our data provide new evidence that, in addition to reducing IKr amplitude (which itself would exacerbate the effect of hERG/IKr blockers), D85N KCNE1 may influence acquired LQTS susceptibility to at least some drugs through a direct effect on hERG/IKr inhibition. The gene discussed is KCNH2; the disease is familial long QT syndrome.